CD33 and breast cancer: The CD33 group of Siglecs was found to play a major role as immune checkpoint molecules in the tumor-microenvironment of BC: inhibiting Siglec-7 (expressed on eosinophils and Natural killer (NK) cells) could induce NK cell lysis of tumor cells [55].